CVS to defend $69B merger with Aetna in upcoming court proceeding

CVS Health is gearing up to defend its $69 billion takeover of the nation’s third-largest health insurer, Aetna, The Wall Street Journal reported. The pharmacy retailer has already integrated with Aetna after the deal was approved by regulators and closed last year, but a U.S. District judge has concerns about the antitrust issues imposed by the merger and has set a three-day proceeding this week to hear testimony from industry stakeholders.

CVS had previously asked Judge Richard Leon to block the witness testimony of opponents of the deal, who are scheduled to speak in court. The American Medical Association is one of those voices and has been vocal about anti-competition concerns about the merger. Six witnesses will be allowed to testify during the proceeding, which begins Tuesday.

The transaction was approved by the Department of Justice, but Judge Leon has been critical of that decision, citing worries that the DOJ rubber stamped the deal without doing enough to protect competition. Aetna agreed to sell its Medicare Part D business as part of the DOJ’s approval of the merger. However, it “isn’t clear” what would happen if the judge rejects the deal between the companies and the DOJ.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.